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Abstract
Background: Aboriginal children living in Australian remote communities are at high risk of early and persistent
otitis media, hearing loss, and social disadvantage. Streptococcus pneumoniae and non-typeable Haemophilus
influenzae (NTHi) are the primary pathogens. We compared otitis media outcomes in infants randomised to either a
combination of Synflorix™ (PHiD-CV10, with protein D of NTHi) and Prevenar13™ (PCV13, with 3, 6A, and 19A), with
recommended schedules for each vaccine alone. We previously reported superior broader overall immunogenicity
of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months.
Methods: In an open-label superiority trial, we randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to
either Prevenar13™ (P) at 2–4-6 months (_PPP), Synflorix™ (S) at 2–4-6 months (_SSS), or Synflorix™ at 1–2-4 months
plus Prevenar13™ at 6 months (SSSP). Ears were assessed using tympanometry at 1 and 2 months, combined with
otoscopy at 4, 6, and 7 months. A worst ear diagnosis was made for each child visit according to a severity
hierarchy of normal, otitis media with effusion (OME), acute otitis media without perforation (AOMwoP), AOM with
perforation (AOMwiP), and chronic suppurative otitis media (CSOM).
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Results: Between September 2011 and September 2017, 425 infants were allocated to _PPP(143), _SSS(141) or
SSSP(141). Ear assessments were successful in 96% scheduled visits. At 7 months prevalence of any OM was 91, 86,
and 90% in the _PPP, _SSS, and SSSP groups, respectively. There were no significant differences in prevalence of
any form of otitis media between vaccine groups at any age. Combined group prevalence of any OM was 43, 57,
82, 87, and 89% at 1, 2, 4, 6, and 7 months of age, respectively. Of 388 infants with ear assessments at 4, 6 and 7
months, 277 (71.4%) had OM that met criteria for specialist referral; rAOM, pOME, or CSOM.
Conclusions: Despite superior broader overall immunogenicity of the combination schedule at 7 months, and early
superiority of PHiD-CV10 compared to PCV13 at 4 months, there were no significant differences in prevalence of
otitis media nor healthy ears throughout the first months of life.
Trial registration: ACTRN12610000544077 registered 06/07/2010 and ClinicalTrials.gov NCT01174849 registered 04/
08/2010.
Keywords: Aboriginal, Infant, Otitis media, Pneumococcal conjugate vaccines, Combination schedule, PCV13, PHiD-
CV10, 3-arm randomised controlled trial, Head-to-head
Background
A 2008 analysis of the global burden of acute and
chronic suppurative otitis media (AOM and CSOM) es-
timated an overall CSOM incidence rate of 4.76 per
thousand people, 22.6% cases in under five-year-old chil-
dren. In the first year of life, the lowest CSOM incidence
rate was 1.59 per thousand in High Income Asia Pacific,
the highest was in Oceania (36 per thousand) [1]. Aus-
tralian Aboriginal and non-Aboriginal data were in-
cluded in Oceania, combined and weighted by
population size. The original national study of otitis
media diagnoses in Australian primary healthcare set-
tings reported that Aboriginal and Torres Strait Islander
children were significantly more likely to have severe
OM, particularly “discharging ears” which was 40-fold
higher [2]. In remote Northern Territory (NT) commu-
nities, longitudinal birth cohort studies conducted in the
pre- and post- 7-valent pneumococcal conjugate vaccine
(PCV7) eras and including a maternal pneumococcal
polysaccharide vaccination trial all found early nasopha-
ryngeal colonisation and concomitant onset of otitis
media (OM) within weeks of birth [3–5]. OM generally
persisted throughout the first year of life, including 12%
having chronic suppurative otitis media (CSOM) at 12
months of age, and less than 10% having bilaterally nor-
mal middle ears [4]. A West Australian study conducted
in the early years of the PCV7 era also found that preva-
lence of OM and hearing loss were around 40% during
first year of life [6]. Recent analyses using data-linkage
has provided evidence that Aboriginal children with a
history of hearing loss on entering school are at in-
creased risk of vulnerability on entering school, [7] poor
school attendance [8] and performance, [9] and substan-
tiated child maltreatment [10].
During surveillance studies in the NT, culture of ear
discharge from 83 cases of acute otitis media with per-
foration (AOMwiP) or CSOM in PCV7-vaccinees
detected non-typeable Haemophilus influenzae (NTHi)
in 58% cases and PCV7-type pneumococci in 5%, com-
pared to 55 and 17%, respectively in non-PCV historic
controls [11].
Few early-intervention trials for prevention or treat-
ment of OM have been conducted in this population.
One randomised controlled trial reported that long term
antibiotics compared to placebo increase the resolution
of OME and prevented progression to tympanic mem-
brane perforation (TMP), with no increase in bacterial
resistance [12]. Whilst effective, long term adherence is
difficult and prevention strategies are the preferred
approach.
At commencement of this trial, clinical trials of the ef-
fect of PCV7 on all-cause AOM found 6% relative risk
reduction (RRR) in low-risk infants, and a lack of effect
in a small RCT in high-risk infants [13]. The RRR was
around 20% for pneumococcal AOM and 10% for recur-
rent AOM. The effect of a pre-cursor to PHiD-CV10,
PD-11Pn, on all-cause AOM was 34% in healthy infants
[14]. In the Northern Territory the childhood vaccin-
ation schedule transitioned through three PCVs over the
period 7-valent PCV7 (2001 to 2009), ten-valent
pneumococcal non-typeable Haemophilus influenzae
protein D conjugated vaccine, PHiD-CV10 (2009 to
2011), and 13-valent PCV13 (from 2011) (see Table 1
and below for PCV13 and PHiD-CV10 formulations).
Cross sectional surveys conducted prior to and during
this current trial identified significant but modest reduc-
tions in the prevalence of severe OM and a significant
reduction in NTHi-culture-positive middle ear discharge
in PHiD-CV10 vaccinees compared to the PCV7 vacci-
nees [15–18]. The Cochrane review of PCVs in the pre-
vention of all-cause acute otitis media was updated
during the course of this RCT. RCTs of new PCVs in-
cluding PHiD-CV10 were underway (including this
RCT) and therefore not able to be included [14]. Our
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RCT was the only study proposing to evaluate a combin-
ation of PCVs within the primary series.
Objectives and hypotheses
We proposed that infants at high risk of early mixed in-
fections would benefit from both PHiD-CV10 (Syn-
florix™, S) and PCV13 (Prevenar13™, P) given in the
primary course schedule. We designed a 3-arm rando-
mised controlled trial comparing a novel 4-dose primary
course schedule of PHiD-CV10 at 1, 2, and 4 months
plus PCV13 at 6 months (SSSP group) with standard 2–
4-6-month schedules of each vaccine (_PPP and _SSS
groups). To date we have reported primary and second-
ary immunogenicity and safety outcomes; the SSSP
schedule was safe, and from 2months of age immuno-
genicity was superior overall [19]. This paper reports oti-
tis media outcomes by vaccine group at 1, 2, 4, 6 and 7
months of age. We also use data combined from all
groups to describe the dynamics and analyse risk factors
of otitis media in the first months of life.
Methods
Details of the trial protocol have been published [20].
Brief summaries are provided.
Trial design
PREVIX_COMBO is an open-label parallel superiority
3-arm (1:1:1) trial.
Setting
The trial took place in five remote Aboriginal and
Torres Strait Islander communities in the Northern Ter-
ritory and Western Australia [20]. The PREVIX_
COMBO trial was approved by the relevant Human Re-
search Ethics Committees [20].
Nomenclature used in this manuscript are: italics P
and S indicate vaccine (Prevenar13™ or Synflorix™) re-
ceived at the time point of interest, and to indicate the
comparison of interest (i.e. _PPP, _SSS, and SSSP at 2
months, _PPP, _SSS, and SSSP at 4 months, _PPP, _SSS,
and SSSP at 6 months, and _PPP, _SSS, and SSSP at 7
months).
Table 1 Schedule of enrolment, interventions, and assessments
Study period
allocation post allocation
Study visit number 1 1 2 3 4 5
Age (months) 1 1 2 4 6 7
Eligibility screen x
Informed consent signed x
Randomisation x
Interventions – Pneumococcal conjugate vaccines
Prevenar13 (_PPP) _ P P P
Synflorix (_SSS) _ S S S
COMBO (SSSP) S S S P
RotarixR x x
InfanrixR Hexa x x x
Outcome assessments
Risk factor data and interviews
Fixed e.g. sex, birthweight, gestational age, maternal education x
Not fixed e.g. household occupancy, smoke exposure, breastfeeding x x
Blood draw (heel, finger prick, or venepuncture) x* x* x
Ear assessment
Tympanometry x x x x x
Video otoscopy x x x
Nasopharyngeal swab x§ x x x x
General health (skin, chest, nose, temp, weight, length) and medical record review x x x x x
Note: Outcomes of all procedures will be published in separate reports
*blood draw occurs at either 2 months or 4 months of age (decided by a random process). § NP swab collection at one month of age commenced late 2014 (NT)
or 2015 (WA). S is PHiD-CV10 (Synflorix™). P is PCV13 (Prevenar13™)
PCV13 contains serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, and 23F
PHiD-CV10 contains serotypes 1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19F, 23F, and protein D of non-typeable Haemophilus influenzae
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Participants
Parents and families were provided with information
about the studies from pregnancy and provided written
informed consent and assent (from mothers younger
than 16 years of age) at infant age 28 to 38 days of age.
Inclusion criteria: Infants 28 to 38 days of age with gesta-
tional age > 32 weeks, eligible for routine immunisations,
first born if twins, and whose families intended to re-
main in one of the five participating communities until
infant age 7 months [20].
Procedures and interventions
Research nurses were trained in giving vaccines and
in standardised ear and general health checks. See
Table 1 for schedule of procedures. Infants were ran-
domised using a computer-generated sequence strati-
fied by community and allocated (1:1:1) to one of
three vaccine schedules: _PPP, _SSS or SSSP. Details
of vaccine formulations are given elsewhere [20].
Briefly, ten-valent pneumococcal non-typeable Hae-
mophilus influenzae conjugated vaccine, PHiD-CV10
(Synflorix™) contains ten pneumococcal serotypes,
most of which are conjugated to protein D of H.
influenzae. 13-valent pneumococcal conjugate vaccine,
PCV13 (Prevenar™) has three additional serotypes, 3,
6A, and 19A, and all are conjugated to CRM197.
Relevant concomitant care
Throughout this study, the Australian Indigenous infant
vaccination schedule was EngerixB™ at birth, RotarixR at
2–4 months, InfanrixR Hexa, and (for non-study
participants) Prevenar13 at 2–4-6 months. Study staff
provided treatment or referral for all concomitant condi-
tions according to local guidelines.
Secondary outcomes: otitis media
Ear assessments were made at scheduled study visits
at 1, 2, 4, 6, and 7 months by research nurses trained
in paediatric video otoscopy and tympanometry. Diag-
nostic categories (see Table 2) were made according
to national guidelines for otitis media in Aboriginal
and Torres Strait Islander populations and managed
according to these and local guidelines (Central Aus-
tralian Rural Practitioners Association Standard Treat-
ment Manual). Tympanometry-only was used at 1
and 2 months of age, and both otoscopy and tympa-
nometry were used at all subsequent visits. At 1 and
2 months of age a diagnosis of either normal (type A
tympanogram) or OM (type B (flat) tympanogram)
was made. For each child and time point a worst ear
diagnosis and laterality were allocated as this deter-
mines medical management. The hierarchy of increas-
ing severity was normal, OME, AOMwoP, DP,
AOMwiP, and CSOM. Dry perforations were detected
on two occasions and have been excluded from
analyses.
Statistical analysis
The study sample size was estimated for analysis of im-
munogenicity. With this sample size we estimate 55%
power to detect a doubling in the proportion of children
free from OM at 7 months in the SSSP group (20%)
compared to either _SSS or _PPP groups (10%), and 70%
Table 2 Otitis media abbreviations and definitions [21].
OM Otitis media All forms of inflammation and infection of the middle ear.
OME Otitis media with effusion, “glue ear” Presence of fluid behind the tympanic membrane without any acute symptoms
or signs of inflammation.
pOME Persistent otitis media with effusion OME for more than 3months without any acute symptoms.
AOMwoP Acute otitis media without perforation The presence of fluid behind the tympanic membrane plus at least one of the
following: bulging tympanic membrane, red tympanic membrane, fever, ear
pain or irritability.
AOMwiP Acute otitis media with perforation Discharge of pus (otorrhoea) through a small perforation (hole, generally < 2% of
the pars tensa) in the tympanic membrane within the last 2 weeks.
rAOM Recurrent acute otitis media The occurrence of 3 or more episodes of AOM in a 6-month period, or occurrence
of 4 or more episodes in the last 12 months.
CSOM Chronic suppurative otitis media Persistent discharge of pus (otorrhoea) through a perforation (hole) in the tympanic
membrane lasting 2 weeks or more and tympanic membrane perforation large
enough to allow penetration of topical antibiotics into the middle ear space
(generally > 2% of the pars tensa).
DP Dry perforation or inactive CSOM Presence of a perforation (hole) in the tympanic membrane without any signs of
discharge or fluid behind the tympanic membrane.
TTO Tympanostomy Tube otorrhoea Discharge of pus (otorrhoea) through tympanostomy tubes (or “grommets”) in situ.
supp OM Suppurative otitis media Combined AOMwoP, AOMwiP, or CSOM.
TMP Tympanic membrane perforation Combined AOMwiP, DP, or CSOM
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power when compared to _PPP and _SSS groups com-
bined (10%). Vaccine group comparisons were tested
with Fisher’s exact test for the proportion of infants with
each diagnosis of otitis media at each timepoint; 95%
confidence intervals (95%CI) were calculated. An
intention to treat approach was used, including all avail-
able data. Longitudinal patterns of ear disease from 4
months of age are described from available data. We also
conducted post-hoc logistic regression analyses of risk
factors for any OM, suppurative OM, tympanic
membrane perforation, or bilateral OM at 7 months of
age. We included vaccine schedule, gender, community,
mothers report of infant chest or ear infections, or runny
nose, number of recent clinic visits for ear problems,
family (mother and sibling) history of ‘runny ears’, num-
ber of other children the mother had, number of chil-
dren under the age of 5 years in the household, breast
and bottle feeding, maternal smoking during pregnancy,
mother current smoker, smoker in the household, ex-
posure to fire smoke. Risk factors with univariate p <
425 Randomised at 1 month of age
141 allocated to Synflorix 141 allocated to combination  143 allocated to Prevenar 
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0.10 were included in multivariable logistic regression
model for each OM outcome. All data were analysed
using Stata/IC 15.1 [22].
Data safety monitoring
The study was overseen by an independent Data Safety
and Monitoring Board (iDSMB).
Role of funding source
The funders had no role in design, collection, analysis,
interpretation of data, writing the report or decision to
submit for publication. As corresponding author, AJL
had full access to all the data in the study and had final
responsibility for the decision to submit for publication.
AJL was not paid by any agency to write this article.
Results
Five communities commenced between September
2011 and August 2014. Of 1018 pregnancy notifica-
tions, 593 were excluded, 425 infants were rando-
mised to _PPP (143), _SSS (141) or SSSP (141). 396
(93%) infants were randomised within the study win-
dow of 28 to 38 days of age (Fig. 1). Final randomisa-
tion of 425 infants occurred on 21st September 2017.
Overall, infant birth characteristics were similar
between groups (Table 3). Ear assessments were
achieved in at least 90% infants across vaccine groups
and time points (Fig. 1). Exclusion of protocol devia-
tions or violations made no difference to our findings.
Baseline characteristics
There were no substantial vaccine group differences in
key risk factors for OM (Table 3).
Prevalence of bilaterally normal ears, by vaccine group
and age
Prior to vaccination, at one month of age, tympano-
metry identified bilateral normal ears in 57, 59, and
54% infants in the _PPP, _SSS and SSSP groups, re-
spectively. At 2 months, following a single dose of
PHiD-CV10 in the SSSP group the prevalence of nor-
mal ears was 40, 48, and 40%, respectively. At 4
months, following a single dose of vaccine in the
_PPP and _SSS groups and following two doses in the
SSSP group, these figures were 20, 20, and 16%, re-
spectively. At 6 months, following 2 doses in the
_PPP and _SSS groups and three doses in the SSSP
group, bilateral normal ears were detected in 10, 14
and 14%, and at 7 months 9, 14, and 10%. There were
no statistically significant differences in the prevalence
Table 3 Baseline Characteristics
Characteristics Prevenar13 (_PPP) Synflorix (_SSS) Combo (SSSP)
N = 143 N = 141 N = 141
Sex /gender Male 77/143 (54%) 69/141 (49%) 70/141 (50%)
Gestational age at birth (Weeks) Mean (SD) 38·4 (1·42) 38·4 (1·40) 38·1 (1·62)
Birth weight (kg) Mean (SD) 3·15 (0·47) 3·19 (0·49) 3·07 (0·53)
Weight at randomisation (kg) Mean (SD) 4·26 (0·54) 4·24 (0·61) 4·04 (0·68)
Age at randomisation (days) Mean (SD) 33·1 (3·33) 32·5 (3·77) 32·5 (3·94)
Community 1 Wurrumiyanga 29/143 (20%) 32/141 (23%) 30/141 (21%)
2 Wadeye 53/143 (37%) 50/141 (36%) 50/141 (36%)
3 Kununurra 26/143 (18%) 25/141 (18%) 27/141 (19%)
4 Alice Springs 7/143 (5%) 6/141 (4%) 6/141 (4%)
5 Maningrida 28/143 (20%) 28/141 (20%) 28/141 (20%)
Have any of your other children had runny ears? Yes 19/98 (19%) 22/97 (23%) 19/93 (20%)
Do you have other children? Yes 120/123 (97.6%) 117/125 (93.6%) 114/121 (94.2%)
Are you breast feeding only? Yes 98/117 (84%) 98/115 (85%) 93/114 (82%)
Are you breastfeeding? Yes 120/124 (97%) 117/124 (94%) 116/121 (96%)
Are you bottle feeding only? Yes 4/123 (3%) 6/120 (5%) 4/119 (3%)
Are you bottle feeding? Yes 24/122 (20%) 26/125 (21%) 25/119 (21%)
Did you smoke when you were pregnant? Yes 58/119 (49%) 60/124 (48%) 61/120 (51%)
Does anyone smoke at your house? Yes 27/124 (22%) 31/125 (25%) 22/121 (18%)
Do you cook with or sit near a wood fire? Yes 23/123 (19%) 22/125 (18%) 28/121 (23%)
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of bilaterally normal ears between vaccine groups at
any age (Table 4).
Prevalence of any OM or bilateral OM by age, and of each
diagnostic category, by vaccine group and age
At the primary endpoint of 7 months the prevalence of
any OM was 91, 86, and 90% in the _PPP, _SSS, and
SSSP groups. There were no statistically significant dif-
ferences at any age in any OM (Fig. 2) or bilateral OM
(Supplementary Table 1) between vaccine groups. For
vaccine groups combined, any OM (in one or both ears)
was detected in 43% infants at one month and 57% at 2
months, 82% at 4 months, 87% at 6 months, and 89% at
7 months. Bilateral OM was detected in 17, 35, 61, 74,
and 76% at 1, 2, 4, 6, and 7 months, respectively (Supple-
mentary Table 1).
At 4, 6, and 7months both tympanometry and otoscopy
were performed, enabling diagnoses of OME, AOMwoP,
AOMwiP, or CSOM (Table 2). The vaccine group preva-
lence of each type of OM at each time point by group
(_PPP, _SSS, and SSSP) was: i) OME in 38, 48, and 44% in-
fants at 4months, 34, 38, and 40% at 6months, and 30, 34,
and 34% at 7months; ii) AOMwoP in 39, 32 and 37% in-
fants at 4months. 43, 40, and 39% at 6months, and 49, 42,
and 49% at 7months; iii) AOMwiP in 3, 0, and 2% infants
at 4months, 10, 4, and 5% at 6months, and 7, 6, and 5% at
7months; iv) CSOM in 0, 1, and 1% infants at 4months, 3,
5, and 2% at 6months, and 6, 3, and 2% at 7months. Any
suppurative OM (AOMwoP, AOMwiP, or CSOM) was the
worst ear diagnosis in 42, 33, and 40% infants at 4months,
56, 48, and 46% at 6months, and 61, 52, and 57% at 7
months. Any tympanic membrane perforation (TMP,
AOMwiP, DP, or CSOM) was the worst ear diagnosis in 3,
1, and 3% infants at 4months, 13, 8, and 7% at 6months,
and 12, 9, and 7% at 7months. There were no statistically
significant differences in any OM diagnosis between vac-
cine groups at any age (Table 4, Figs. 3 and 4).
Patterns of OM in 388 infants who had three successful
consecutive ear assessments at 4, 6, and 7months,
vaccine groups combined
As there were no significant differences between vaccine
groups, we combined data for further analyses by diagno-
sis and age. As we were unable to distinguish OME from
AOM at 1 and 2months, when tympanometry-only was
used, the following analyses use diagnoses from infants
seen at all three visits at 4, 6, and 7months of age.
Overall, bilateral normal ears were rare and overall
were found in just 14% diagnoses (Table 5). Around 37%
infants had a diagnosis of OME, and 41% had AOMwoP.
Tympanic membrane perforations were detected as early
as 4 months (2.3%) and peaked at 7 months of age (10%).
In this age group most perforations were AOMwiP (5%
overall), and CSOM prevalence was almost 4% at age 7
months (Table 6).
Eligibility for specialist referrals
Guidelines recommend referral for specialist assessments
of any child with recurrent AOM (rAOM) defined as
three episodes in 6 months or four in 12 months, persist-
ent OME (pOME) for at least 3 months, or any CSOM
[21]. Recurrent AOMwoP or AOMwiP was detected in
71 (18%); pOME in 47 (12%), and CSOM in 24 (6%) in-
fants. Thus 142 (37%) met standard criteria for referral.
Importantly, an additional 135 (35%) infants had persist-
ent mixed OME with AOMwiP or AOMwoP, making a
Fig. 2 Prevalence (%, 95 confidence interval) of any otitis media, by age and vaccine group
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Fig. 3 Proportion of infants (%) with a worst ear diagnosis* of each form of otitis media, by vaccine group and age (months)**
Fig. 4 Cumulative proportion of infants with any OM, any bilateral OM, any suppurative OM# or any tympanic membrane perforation##, by age
and vaccine group
Leach et al. BMC Pediatrics          (2021) 21:117 Page 10 of 14
total of 277 infants or a staggering referral rate of 71%
(Table 6). Bilateral normal ears were detected at all three
assessments in 4 infants (1%), at one or two assessments
in 110 (28%) infants, and alternating with OME (45),
AOMwoP (54), AOMwiP (9), or CSOM (2) (Table 6).
Transitions from OM to normal middle ear status
between each visit
Transitions from OM to no OM were very rare; 60 of
172 (35%) infants with OM at one month; 30 of 221
(14%) infants with OM at 2 months; 26 of 308 (8%) in-
fants with OME or AOMwoP at 4 months; 27 of 307
(9%) infants with OME or AOMwoP at 6 months. Of 34
infants with AOMwiP at 4 or 6 months, two (6%)
returned to normal at 7 months, and of 15 infants with
CSOM at 4 or 6 months, none returned to normal ears
at 7 months (Supplementary Table 2).
In univariate analyses we found no statistically signifi-
cant risk factors for bilateral OM. For any OM, one
community had an Odds Ratio (OR) of 0.37 (p = 0.03)
compared to reference community. Statistically signifi-
cant risk factors for suppurative OM and tympanic
membrane perforations at 7 months were presence of
prior ear discharge reported by the mother (OR 5.39 p <
0.001 and OR 55.6 p < 0.001, respectively), number of re-
cent visits to the clinic for ear problems (OR 2.13 p =
0.03 and up to 8.71 p < 0.001, respectively), recent chest
infections (OR 2.44 p = 0.01 for TMP only), recent runny
nose (OR 2.29 p = 0.01 for TMP only), and mother hav-
ing other children (OR up to 4.68 p < 0.01 for suppura-
tive OM only). A multivariable analysis using a
univariable approach (includes all predictors with p <
0.10) identified ear discharge (OR 4.98 p = 0.001) and
number of children the mother had (OR up to 5.87 p =
0.006) as significant risk factors for suppurative OM. Ear
discharge (OR 52.04 p < 0.0001) and number of visits to
the clinic for ear problems (OR up to 5.45 p = 0.003)
were significant risk factors for any TMP (Supplemen-
tary Table 3 for suppurative OM, any OM, and bilateral
OM).
Discussion
Despite indications of potential early and broadened im-
mune protection from vaccine type pneumococci and
NTHi, [19] our clinical findings clearly demonstrate a
failure of this strategy to prevent early onset of OM in
this population. We found no statistically significant dif-
ferences in any OM diagnosis between vaccine groups at
any age. Our study shows that PCVs do not directly or
via herd effects, prevent early onset of all-cause OM dur-
ing or one month after completing primary course
schedules. Although tympanocentesis is not performed
in Australia, nasopharyngeal carriage studies and culture
of middle ear discharge during spontaneous perforation
provide a close proxy for middle ear microbiology and
confirm non-vaccine type pneumococci and NTHi as
dominant pathogens in OM [11, 18]. We will report
nasopharyngeal carriage outcomes at all timepoints for
infants in this trial. In surveillance studies across the NT
Table 5 Prevalence (n, %) of OM at age 4, 6, and 7 months among 388 infants who had ear assessments at all three timepoints
Age 4months 6months 7months Number of diagnoses
Number of children seen 388 388 388 1163
Worst ear diagnosis
Normal 74 (19.1%) 48 (12.4%) 41 (10.6%) 163 (14.0%)
OME 166 (42.8%) 144 (37.1%) 124 (32.0%) 434 (37.3%)
AOMwoP 139 (35.8%) 157 (40.5%) 184 (47.4%) 480 (41.3%)
AOMwiP 7 (1.8%) 25 (6.4%) 24 (6.2%) 56 (4.8%)
CSOM 2 (0.5%) 13 (3.4%) 15 (3.9%) 30 (2.6%)
Combined OM categories
Supp OM# 148 (38.1%) 195 (50.3%) 223 (57.5%) 566 (48.7%)
TMP## 9 (2.3%) 38 (8.2%) 39 (10.0%) 80 (6.9)
#SuppOM, is suppurative OM which includes AOMwoP, AOMwiP, and CSOM
##TMP is tympanic membrane perforation which includes dry perforation, AOMwiP, and CSOM
Table 6 Proportion (n, %) of infants at 7 months who met
referral criteria for persistent or severe OM, among 388 infants
who had ear assessments at all three timepoints
Referral criteria n (%)
N = 388
Recurrent AOMwoP/AOMwiP (3 episodes within 6 months) 71 (18.3%)
Persistent OME (3 months) 47 (12.1%)
CSOM at least once 24 (6.2%)
Mixed OME/AOM (3 months) 135 (34.6%)
Total referrals 277 (71.4%)
Other
Fluctuating (normal/OM) 110 (28.4%)
Normal (3 months) 4 (1.0%)
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remote communities in 2013 (during this trial) we found
that pneumococcal nasopharyngeal carriage in PCV13-
vaccinated one-year old children was 77%, and the dom-
inant serotypes were 16F (23%) and 15A (10%), followed
by 23F, 11A, 35B, and 19F (each ~ 6%). Carriage of
NTHi was 63% [18]. Respiratory viral infections may also
contribute, although our previous work has shown only
adenovirus is independently associated with AOM (~
13% cases), whereas other viruses exacerbate bacterial
OM through co-infection which increases bacterial load
and risk of AOM [23].
In this high-risk population, and for infants at high-
risk in other populations [24], prevention of early onset
OM is critical as early onset is invariably followed by
persistent and increasingly severe and intractable infec-
tions. Few vaccine studies have reported early otitis
media outcomes, within the primary schedule. A 2016
systematic review of nasopharyngeal carriage following
each primary dose of PCV7 or PHiD-CV10 found no
significant difference between vaccinees and controls at
4 or 6 months, whereas at 7 months vaccinees had lower
carriage of vaccine types, higher carriage of non-vaccine
types [25]. No differences in overall pneumococcal or
NTHi carriage were found at any timepoint. The latest
update of the Cochrane review of pneumococcal vac-
cines for prevention of all-cause or pneumococcal AOM
was to 29 March 2019 [14]. The review evaluated out-
comes of early infancy schedules and administration in
older children. The included studies had a minimum
follow-up duration of 6 months and therefore likely mea-
sured outcomes after the booster dose. The effect of
PHiD-CV10 varied from 6 to 15% RRR in healthy infants
(non-significant) and there was no RCT evaluating otitis
media outcomes of PCV13. The authors noted that in
the absence of RCTs, data from population studies show
further reductions in OM hospitalisations following
PCV13 licensure, compared to PCV7 era [26]. The re-
view also found that PCVs did not reduce all-cause
AOM when administered in high risk infants, after early
infancy, or in older children with a history of respiratory
illness or frequent AOM. There was limited evidence
that administration of PCVs in early infancy may reduce
the risk of recurrent AOM. The authors suggested that
the mechanism for this may be that PCVs prevent early
vaccine-type AOM and thereby disrupt the progression
and chronicity of subsequent all-cause AOM (non-vac-
cine serotype-AOM and NTHi-AOM) [27, 28]. Our
study does not support this hypothesis. Although naso-
pharyngeal carriage of PCV13 serotypes has declined, we
have seen replacement by non-PCV13 serotypes, and on-
going NTHi carriage.
The importance of preventing NTHi and non-PCV13-
type early, persistent and severe OM in this populations
is highlighted by our work. Our analysis of transitions in
OM status during the first 6 months of life found less
than 10% infants with OM had returned to normal
healthy ears at subsequent visits. Where a diagnosis of
bilaterally normal ears was made, this was transient, in-
dicating the importance of regular and opportunistic ear
assessments throughout the first months and years of life
for these children. The National Guide for prevention of
hearing loss in Aboriginal and Torres Strait Islander
populations recommends timely vaccinations, surveil-
lance, exclusive breast feeding, avoidance of smoke ex-
posure, surgical interventions to reduce hearing
impairment, chemoprophylaxis for high-risk children,
and assessment of household overcrowding [29]. Many
of these strategies prevent other infections and are
broadly recommended. However, evidence for preven-
tion of OM is weak or lacking, and where reported, ef-
fect size is generally small [21]. Our univariate and
multivariable analyses of risk factors did not show statis-
tically significant associations between OM and the clas-
sical risk factors, possibly due to high rates of OM with
or without risk factor exposures. All infants in our study
received appropriate management plans for their OM
detected by research nurses at the time of vaccination,
and according to otitis media guidelines for Aboriginal
and Torres Strait Islander children, including education
and guidance about detecting and managing ear and
hearing problems, primary health care and specialist ser-
vice referrals [21]. Very few infants received follow-up
from their primary care providers, nor specialist services.
The failure of these combined efforts to prevent and
treat OM in these infants warrants a much greater local
investment.
A limitation of our study was low sample size and lim-
ited ability to detect small but potentially important clin-
ical differences between vaccines and schedules.
Conclusion
Our study confirms that a multi-modal approach to
otitis media prevention, detection, treatment, and sup-
port for hearing impaired children and their families
will be required to tackle this crisis. Ongoing vaccine
development to broaden pneumococcal serotype
coverage and to elicit protective immune responses to
NTHi is needed globally. New generation vaccines
and schedules must be evaluated in high-risk popula-
tions. In Australia, strategies that address the social
determinants of otitis media in Aboriginal and Torres
Strait Islander children, particularly housing and ac-
cess to quality health care can also contribute to
elimination of childhood hearing impairment and so-
cial disadvantage. These too must be evaluated to en-
sure they are adequate, and that significant change is
achieved.
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